Latest International Expansion News

Temple & Webster Group has reported a record FY25 revenue of $601 million, marking a 21% increase year-on-year, alongside a 43% rise in EBITDA. The company is confidently progressing towards its ambitious $1 billion mid-term revenue target.

Temple & Webster Group delivered a robust FY25 with 21% revenue growth and expanded into New Zealand, reaffirming its ambitious growth and profitability targets for FY26.

Chrysos Corporation reported robust FY25 results driven by record sample volumes and expanded global deployments of its PhotonAssay technology. The company reiterates strong FY26 guidance amid growing international partnerships.

SPC Global Holdings delivered a transformational FY25 with robust financial results and strategic international growth, setting the stage for a confident 25% EBITDA increase in FY26.

Gentrack Group reported a strong FY25 with revenue up 8% and net profit more than doubling, driven by key deployments of its new g2.0 cloud platform and robust growth in its airports division Veovo.

xReality Group Limited reported a robust 36% revenue increase in FY25, driven by rapid expansion of its Operator XR platform and strategic balance sheet improvements. The company’s optimistic outlook for FY26 is underpinned by new contracts, AI investments, and international distributor expansion.

ECS Botanics has achieved a milestone with direct-to-consumer sales exceeding 60% of total revenue, driven by the launch of innovative sugar-free THC gummies and a strategic distribution partnership.

Spacetalk Ltd reveals a successful pivot to a software-led, hardware-enabled model, reporting 12% revenue growth and expanding into 15 international markets. The company targets $20–25 million in recurring revenue for 2026, underpinned by new product launches and strategic telco partnerships.

AFT Pharmaceuticals reports a robust 33% revenue increase in the first half of FY26, driven by strong ANZ market performance and expanding international presence. The company advances its R&D pipeline and targets NZ$300 million revenue for FY27 amid strategic global expansion.

AFT Pharmaceuticals delivered a robust first half for FY26, posting 33% revenue growth and a return to profitability, driven by strong Australian sales and recovery in Asia and international markets. The company is advancing its global footprint and R&D pipeline, positioning for sustained growth.

AFT Pharmaceuticals has reported a robust first half of FY26, posting a 33% revenue increase to a record $114.9 million and returning to profitability amid strong growth in Australia and international markets. The company’s advancing R&D pipeline and strategic licensing deals position it well for ambitious FY27 targets.

Acusensus Limited has raised its FY26 revenue guidance to $83-$87 million, driven by significant new contracts in the US and New Zealand and expansions in Australia. This upgrade signals strong momentum in the company’s AI-powered road safety enforcement business.